Antonio López Pousa
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Hospital Sant Pau · Hospital de la Santa Creu i Sant Pau de Barcelona
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antonio López Pousa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:31 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03277924 · Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasGrupo Espanol de Investigacion en Sarcomas · completed · Soft Tissue Sarcoma, Bone Sarcoma · principal investigator
- Ph2NCT03275818 · Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing SarcomaGrupo Espanol de Investigacion en Sarcomas · completed · Tumor, Desmoplastic Small Round Cell, Adult, Tumor, Desmoplastic Small Round Cell, Childhood, Sarcoma, Ewing · principal investigator
- Ph2NCT03242382 · Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.Grupo Espanol de Investigacion en Sarcomas · unknown · Soft-tissue Sarcoma, Osteosarcoma, Chordoma · principal investigator
- Ph2NCT02066285 · Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaGrupo Espanol de Investigacion en Sarcomas · completed · Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma · principal investigator
- Ph2NCT01264328 · Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck CancerGrupo Español de Tratamiento de Tumores de Cabeza y Cuello · completed · Head and Neck Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:31 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 374 citationsRCR 14.4
- 163 citationsRCR 5.4
- Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Clin Cancer Res · 2012107 citationsRCR 2.7
- 63 citationsRCR 2.2
- Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.Br J Cancer · 201734 citationsRCR 1.2
- Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.Clin Cancer Res · 202422 citationsRCR 2.0
- Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.Mol Cancer Ther · 202115 citationsRCR 0.8
- Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open · 20253 citationsRCR 1.1